DDD · 3D Systems
Conviction · Low · more likely to lag the S&P 500 over the next three months
Wrong if: a daily close above $2.17
Note written ·
Price against the kill line
29.5% clear of its kill line on the 13 November 2026 close.
How to read this
This note expects the shares to lag the market, so its kill line sits above the price: a close above the red mark would prove the view wrong. Prices run from low on the left to high on the right. The dot is where the stock closed on 13 November 2026, left of the mark while it is below the line; a dot right of the mark has closed through it.
The scale is stretched near the line, so close calls are easy to see. More than 8% from the line, the stock reads well clear, with a hollow dot to show the figure is off the drawn scale.
The kill line is the research note's own test. The portfolio sells on business facts, not on a price. How the portfolio decides
Three months against the kill line
Daily closes, to . Red: the kill line, a daily close above $2.17, on record since 11 November 2026. The shares are down 58.0% since the close; the S&P 500 is down 2.1% over the same sessions. Figures in the note can cover a different window.
Kill line
A daily close above $2.17, higher than every close since the 5 November 2026 drop, would show the shares recovering and leading. Q4 2026 revenue above the $103 million top of the guide would point the same way.
Research onlyNot in the portfolio.
Key figures from the filings · Technology
Quarter to 30 September 2026, filed 4 November 2026; valuation at the 13 November 2026 close
- Revenue, latest quarter ($M)
- 99.3
- Revenue, change on a year (%)
- +8.8
- Gross margin (%)
- 35.0
- Operating margin (%)
- −24.7
- Free cash flow, four quarters ($M)
- −42.5
- Net cash, cash less debt ($M)
- −19.5
- Enterprise value to sales (×)
- 0.7
- Free-cash-flow yield (%)
- −16.7
All filed numbers
What 3D Systems reports to the SEC in its quarterly and annual filings. Each group states its period and filing date once; a figure dated otherwise says so. Built from the filings known on .
| Quarter to | Revenue ($M) | On a year (%) | Gross margin (%) | Operating margin (%) |
|---|---|---|---|---|
| first filed | 99.3 | +8.8 | 35.0 | −24.7 |
| first filed | 94.6 | −0.3 | 36.4 | −11.3 |
| first filed | 95.5 | +1.1 | 35.9 | −7.0 |
| first filed | 106 | −4.3 | 30.8 | −21.3 |
| first filed | 91.2 | −19.2 | 32.3 | −23.4 |
| first filed | 94.8 | −16.3 | 38.1 | −16.2 |
| Pre-tax income ($M) | −32.0 |
| Net income ($M) four quarters: −70.3 | −33.5 |
| Diluted shares, change on a year (%) against the quarter to 30 September 2025 | +30.0 |
| Operating cash flow ($M) | −32.2 |
| Capital spending ($M) | 10.3 |
| Free cash flow ($M) | −42.5 |
| Cash and short-term investments ($M) | 72.3 |
| Debt ($M) non-current long-term debt plus current maturities | 91.8 |
| Net cash, cash less debt ($M) | −19.5 |
| Deferred revenue ($M) −27.3% on a year | 23.1 |
| Backlog, orders not yet delivered ($M) at 31 December 2025, filed 9 March 2026 | 6.5 |
| Receivables ($M) | 86.2 |
| Inventory ($M) | 119 |
| Shareholders' equity ($M) | 247 |
| Market value ($M) | 255 |
| Enterprise value, market value plus net debt ($M) | 274 |
| Enterprise value to sales (×) | 0.7 |
| Enterprise value to operating income (×) | Not meaningful |
| Price to earnings (×) | Not meaningful |
| Price to book value (×) | 1.0 |
| Free-cash-flow yield (%) | −16.7 |
Short interest (FINRA, settled 15 October 2026, published 26 October 2026): 26.2% of shares outstanding sold short, 15.3 days of average trading to cover, −0.2% since the previous report.
| Window | Bought | Sold |
|---|---|---|
| 90 daysfrom | $0 | $635K |
| 12 monthsfrom | $0 | $635K |
The thesis
3D Systems is more likely to lag the S&P 500 than lead it over the next three months. Q3 revenue met guidance, but the Q4 outlook came in below estimates and the company paired the report with a share-sale program and a debt-for-equity exchange. Q4 2026 revenue against the $100 million–$103 million guide, and how much stock reaches the market, settle the case.
The shares closed at $2.64 on 4 November 2026, the day of the report, and at $1.67 on 5 November 2026, the 52-week closing low. They closed at $1.81 on 11 November 2026, down 50.0% over three months. The company sold 18.9 million new shares at $3.05 in June 2026, so buyers in that offering sit well below their price.
Bullish and bearish views on 3D Systems Corporation
The bull case on 3D Systems Corporation (DDD), in brief: Q3 revenue beat estimates. The bear case: the Q4 outlook missed.
Bull case
- Q3 revenue beat estimates. Sales were $99.304 million against a $97.281 million analyst estimate, and the company's 3 August 2026 range was $96 million–$99 million (Benzinga, 4 November 2026).
- Debt cost falls. The company agreed on 4 November 2026 to exchange all $92.03 million of 5.875% secured convertible notes due 2030 for $85 million of 3.30% convertible notes due 2031, 13,471,138 shares and $20 million in cash (Form 424B5, 5 November 2026). Closing was expected on or about 12 November 2026.
- Healthcare and defense work continues. Healthcare Solutions revenue was $48.1 million in Q2 2026, up 6.8% year over year (company release, 3 August 2026). An Air Force award of $9 million on 10 August 2026 lifted demonstrator-program funding to $27.4 million.
- One legal overhang eased. Bloomberg Law reported on 11 November 2026 that stockholders ended suits against company executives over revenue.
Bear case
- The Q4 outlook missed. The company guided Q4 sales to $100 million–$103 million against a $105.912 million estimate (Benzinga, 4 November 2026). Q3 adjusted loss per share was $0.06 against an estimated $0.04 loss.
- Share supply is growing. The 5 November 2026 prospectus supplement covers up to $42.5 million of stock sold through Cantor Fitzgerald, with commission of up to 3.0%. That comes on top of the 13.47 million exchange shares and 166,420,187 shares already outstanding.
- Cash leaves in the exchange. The $20 million payment to noteholders follows a Q3 adjusted EBITDA (earnings before interest, taxes, depreciation and amortization) guide of a $1 million–$3 million loss, issued 3 August 2026.
- Insiders sold in September. SEC Form 4 filings show the chief financial officer sold 30,000 shares at $3.58 and the chief executive sold 42,686 shares at $3.55, both on 17 September 2026.
- Leadership and legal uncertainty. Chief executive Jeffrey Graves said on 4 August 2026 that he will retire once a successor is appointed. Law firms announced investigations after the earnings report on 6 November 2026.
Price setup
The shares closed at $1.81 on 11 November 2026, below the 50-day average of $3.1 and the 200-day average of $2.77. The 52-week intraday high was $4.12 on 2 June 2026, and the last close is 56.1% below it.
After the 5 November 2026 close of $1.67, the shares rose to $1.92 on 9 November 2026 and then eased to $1.83 and $1.81. The $2.64 close on 4 November 2026 is the pre-report level that any recovery would have to approach.
Catalysts ahead
- ~31 December 2026 (est.): Chief executive successor expected later in 2026. A named successor would end the leadership uncertainty the company disclosed on 4 August 2026.
Elapsed catalysts
- ~12 November 2026 (est.): Expected closing of the exchange of 2030 secured convertible notes. Closing fixes the added share count, the $20 million cash payment and the lower-rate 2031 convertible notes. (passed)
What would change the view
A daily close above $2.17, higher than every close since the 5 November 2026 drop, would show the shares recovering and leading. Q4 2026 revenue above the $103 million top of the guide would point the same way.
What it trades with
The shares have moved on company-specific news: the report, the offering terms and the debt exchange. Additive-manufacturing peers and small-cap industrial stocks move with equity-market risk appetite, but the 5 November 2026 drop came from this company's own announcements.
The evidence, claim by claim (7)
- Q3 2026 sales were $99.304M versus a $97.281M estimate; adjusted EPS was a $0.06 loss versus a $0.04 loss estimate. Benzinga, 3D Systems Q3 2026 results · as of
- Q4 2026 sales guidance is $100M-$103M versus a $105.912M estimate. Benzinga, 3D Systems Q4 guidance · as of
- The company agreed to exchange all $92.03M of 2030 secured convertible notes for $85M of 3.30% convertible notes due 2031, 13,471,138 shares and $20M cash. 3D Systems Form 424B5 prospectus supplement · as of
- At-the-market program for up to $42.5M of common stock through Cantor Fitzgerald, commission up to 3.0% of gross proceeds; 166,420,187 shares outstanding. 3D Systems Form 424B5 prospectus supplement · as of
- CFO Phyllis Nordstrom sold 30,000 shares at $3.58 and CEO Jeffrey Graves sold 42,686 shares at $3.55 in open-market transactions on 17 September 2026. SEC Form 4 filings · as of
- Closes: $2.64 on 4 November 2026, $1.67 on 5 November 2026 (52-week closing low), $1.81 on 11 November 2026; 52-week intraday high $4.12 on 2 June 2026. Daily closing prices · as of
- Healthcare Solutions revenue was $48.1M in Q2 2026, up 6.8% year over year. 3D Systems Q2 2026 results release · as of
Sources
- 3D SYSTEMS CORP - Form 424B5 - FY2026 · sec.gov ·
Related · shared themes
ADPT
Adaptive Biotechnologies
Adaptive Biotechnologies is more likely than not to beat the S&P 500 over three months because clonoSEQ tests rose 46% in the third quarter…
AXGN
Axogen
Axogen's nerve-repair revenue grew 26.2% last quarter and a $754 million prostate market sits outside guidance, giving the shares a modest…
CSTL
Castle Biosciences
Castle Biosciences raised 2026 revenue guidance to $385–395 million and held its 50–52% TissueCypher volume growth plan; the fourth-quarter…
DXCM
DexCom
Dexcom's raised 2026 outlook and 25.3% third-quarter operating margin give the shares a modest edge after a diabetes-device sell-off erased…
See also · stocks to watch